Community Acquired Pneumonia
Conditions
Brief summary
The aim of this work is to assess the benefit of coenzyme Q10 supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community acquired pneumonia
Interventions
DRUGoral coenzymeQ10
60 children with community acquired pneumonia will receive oral coenzymeQ10 in capsule form at a dose of 100-200 mg/kg/day, as adjunct therapy to the usual pneumonia treatment till the recovery of the disease.
Sponsors
Tanta University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Months to 18 Years
Healthy volunteers
No
Inclusion criteria
* All children aged 2 months -18 years with community acquired pneumonia diagnosed by signs and symptoms of CAP including; chest pain, dyspnea, tachypnea, or abnormal auscultatory findings plus focal findings on chest x ray indicating community acquired pneumonia
Exclusion criteria
* Children with immunodeficiency, chronic lung disease, malignancy, congenital lung anomalies, underlying disorder impacting respiration i.e. genetic, metabolic, neuromuscular disorders, children with CHD affecting the pulmonary blood flow.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time of clinical stability | 3-5 days | — |
| Systemic Immune-Inflammation Index | 5 days | — |
| Serum C-Reactive Protein to Albumin Ratio (CRP/Albumin Ratio) | 5 days | The serum C-reactive protein to albumin ratio (CRP/albumin ratio) will be calculated as a single composite outcome measure using laboratory values obtained from the same blood sample. |
| Normalization of respiratory rate | 3 days | — |
| Normalization of temperature | 3 days | — |
| Normalization of oxygen saturation | 3 days | — |
| Normalization of Feeding Behavior Assessed by Oral Intake Tolerance | 3 days | Normalization of feeding refusal will be assessed by evaluating the child's ability to tolerate age-appropriate oral feeding without refusal over a 3-day observation period. |
| Serum C-Reactive Protein (CRP) Level | 5 days | Blood samples will be collected, and CRP concentration will be expressed in milligrams per liter (mg/L). |
| Serum Lactate Dehydrogenase (LDH) Level | 5 days | LDH concentration will be reported in units per liter (U/L) from venous blood samples. |
| Prognostic Nutritional Index | 5 days | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Requiring Surgical Intervention | 21-30 days | This outcome measures whether a participant undergoes any surgical intervention related to the study condition during the follow-up period. Surgical intervention is defined as any operative procedure performed under general or regional anesthesia, as documented in the medical record. The outcome will be recorded as a binary variable (Yes/No) for each participant and summarized as the number and proportion of participants requiring surgical intervention. |
| Length of hospital stay | 10-21 days | — |
Countries
Egypt
Contacts
Primary ContactAhmed Elniny Lecturer of Pediatrics, MD
Outcome results
None listed